Inoviq Ltd (ASX: IIQ) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Inoviq Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $54.29 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 92.02 million
Earnings per share -0.147
Dividend per share N/A
Year To Date Return -53.97%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Inoviq Ltd (ASX: IIQ)
Latest News

Female scientist working in laboratory for Race Oncology
Healthcare Shares

What’s going on with the Inoviq (ASX:IIQ) share price today?

The company is set to finish the week on a high note.

Read more »

A male Avita Medical doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

Why has the BARD1 (ASX:BD1) share price vanished from the ASX boards?

Where are BARD1's shares hiding?

Read more »

Vanadium Resources share price person riding rocket indicating share price increase
Share Gainers

BARD1 (ASX:BD1) share price ends stellar day up 41%

BARD1 had a fantastic day...

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

BARD1 Life Sciences (ASX:BD1) share price leaps 16% on US patent news

The company's shares are set to finish the week on a positive note.

Read more »

man jumping along increasing bar graph signifying jump in alumina share price
Share Market News

BARD1 Life Sciences (ASX:BD1) share price jumps on cancer test update

The quest for BARD1's ELISA test takes another step forward.

Read more »

Healthcare Shares

Here’s why the BARD1 (ASX:BD1) share price is falling 7% today

The market is responding poorly to BARD1's fourth-quarter activities

Read more »

share price dropping
Share Fallers

Why BARD1, Imugene, Northern Star, & Silver Lake shares are sinking

It hasn't been a good day for these ASX shares...

Read more »

laboratory workers looking disappointed
Capital Raising

BARD1 (ASX:BD1) share price falls 6% on placement update

The medical diagnostics company has secured the first part of its equity raise...

Read more »

IIQ ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Inoviq Ltd

Formerly BARD1 Life Sciences Limited (ASX: BD1).

IIQ Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
18 May 2022 $0.55 $0.04 7.84% 141,344 $0.53 $0.57 $0.52
17 May 2022 $0.51 $0.00 0.00% 109,324 $0.51 $0.52 $0.51
16 May 2022 $0.51 $0.00 0.00% 175,531 $0.53 $0.54 $0.51
13 May 2022 $0.51 $-0.05 -8.93% 194,896 $0.56 $0.58 $0.51
12 May 2022 $0.56 $0.01 1.82% 205,312 $0.56 $0.57 $0.53
11 May 2022 $0.55 $-0.01 -1.77% 132,323 $0.57 $0.57 $0.55
10 May 2022 $0.57 $0.01 1.80% 236,446 $0.56 $0.62 $0.56
09 May 2022 $0.56 $-0.02 -3.48% 218,237 $0.58 $0.59 $0.56
06 May 2022 $0.58 $0.00 0.00% 178,451 $0.58 $0.62 $0.57
05 May 2022 $0.58 $0.01 1.77% 352,983 $0.58 $0.59 $0.56
04 May 2022 $0.57 $-0.03 -5.08% 210,821 $0.59 $0.61 $0.57
03 May 2022 $0.59 $0.02 3.51% 340,330 $0.57 $0.61 $0.57
02 May 2022 $0.57 $0.01 1.79% 895,528 $0.60 $0.60 $0.56
29 Apr 2022 $0.56 $-0.01 -1.74% 277,760 $0.57 $0.60 $0.56
28 Apr 2022 $0.58 $-0.06 -9.52% 457,649 $0.63 $0.63 $0.57
27 Apr 2022 $0.63 $-0.04 -6.02% 200,448 $0.64 $0.65 $0.63
26 Apr 2022 $0.67 $-0.01 -1.48% 119,110 $0.68 $0.68 $0.63
22 Apr 2022 $0.68 $-0.01 -1.46% 211,677 $0.68 $0.69 $0.68
21 Apr 2022 $0.69 $-0.01 -1.43% 215,397 $0.73 $0.73 $0.68
20 Apr 2022 $0.70 $-0.01 -1.41% 338,826 $0.71 $0.72 $0.70

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
13 May 2022 Philip (Phil) Powell Buy 20 $10,620
On-market trade. Average Price
06 May 2022 Geoffrey Cumming Buy 32 $20,082
On-market trade.
02 May 2022 Philip (Phil) Powell Buy 50 $29,000
On-market trade.
13 Dec 2021 Geoffrey Cumming Issued 500 $520,000
Issue of options. As per announcement on 22/12/2021.
13 Dec 2021 Allan Cripps Issued 500 $520,000
Issue of options.
13 Dec 2021 Philip (Phil) Powell Issued 500 $520,000
Issue of options.
13 Dec 2021 Robert (Max) Johnston Issued 500 $520,000
Issue of options.
21 Oct 2021 Philip (Phil) Powell Buy 40 $43,670
On-market trade.
24 Aug 2021 Philip (Phil) Powell Buy 19 $29,998
Participation in share purchase plan.
24 Aug 2021 Geoffrey Cumming Buy 19 $29,998
Participation in share purchase plan.
24 Aug 2021 Robert (Max) Johnston Buy 19 $29,998
Participation in share purchase plan. As per announcement on 27/08/2021

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mrs Pauline Anne Collinson Company Secretary Nov 2001
Mrs Collinson has worked for the Company for 23 years and has held the position of Company Secretary for 14 years. She is also the Company Secretary of Tanami Gold NL (ASX:TAM).

Professor Allan Cripps Non-Executive Director Jan 2020
Prof Cripps is an academic, clinical scientist and health services leader, having made contributions in immunology, diagnostics, and health services delivery. From 2005 to 2016, Prof Cripps was the Pro Vice Chancellor (Health) at Griffith University and is currently a research Prof at Griffith University, leading the Mucosal Immunology Research Group within the Menzies Health Institute Queensland. Prof Cripps had near 20 years' experience in the health and pharmaceutical industries before becoming a full-time academic focusing his research on mucosal immunology, respiratory tract infections, vaccine development and diagnostics. He has published over 300 peer reviewed scientific papers, presented at numerous international scientific conferences, received over $17 million in Government and industry grant funding and is co-inventor on several international patents in the fields of diagnostics and vaccine protein antigens. He is a fellow of the Australian Academy of Health and Medical Scientists, the Australian Society for Microbiology, the Australian Institute of Medical Scientists, the Institute of Biomedical Scientists (UK) and the Australasian College of Health Service Management. In 2015 he was awarded the Order of Australia (AO) for distinguished service to tertiary education as a senior administrator and to public health as a leading immunologist, academic and researcher in the area of mucosal immunisation. Prof Cripps is a Non-Executive Director of Neurotech International Limited (ASX: NTI). He was previously Non-Executive Director of Research Australia (2005 to 2012) and the Gold Coast Hospital and Health Services Board (2011 to 2017). Prof Cripps is a member of the Company's Remuneration Committee and Audit & Risk Committee.
Mr Philip (Phil) John Powell Non-Executive Director Jun 2019
Mr Powell is a Chartered Accountant with experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. Mr Powell is currently a Non-Executive Director of Medical Developments International Ltd (ASX: MVP) and RMA Global Ltd (ASX: RMY). He was a former Non- Executive Director of PolyNovo Ltd (ASX: PNV). Mr Powell is the Chair of the Company's Audit & Risk Committee
Mr Geoffrey A. Cumming Non-Executive ChairmanNon-Executive Director Jul 2020
Dr Cumming has held senior roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Dr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the fastest growing and most profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Dr Cumming was successful in designing and securing key funding arrangements through a skilful range of capital raising initiatives, including large government grants, partnering and co-development deals. His most recent executive role was as Managing Director / CEO of Anteo Diagnostics Ltd (ASX: ADO). He is currently a Nonexecutive Director of Anteo Diagnostics Ltd and was previously Chairman of Sienna Cancer Diagnostics Ltd and a Nonexecutive Director of Medical Australia Ltd (ASX: MLA). Dr Cumming is the Chair of the Remuneration Committee
Mr Robert (Max) Maxwell Johnston Non-Executive Director Jun 2019
Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the world's largest medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston's career also included senior roles with Diageo and Unilever in Australia, Africa, and Europe. Mr Johnston has also held several prominent industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Skills Management Institute (ASMI). Mr Johnston has had extensive overseas experience during his career in leading businesses in both Western and CentralEastern Europe and Africa as well as the Asia-Pacific region. Mr Johnston is currently Non-Executive Chairman of AusCann Group Holdings Ltd (ASX: AC8) and a Non-Executive Director of Medical Developments International Ltd (ASX: MVP). He was a former Non-Executive Director of Enero Group Limited (ASX: EGG) and PolyNovo Ltd (ASX: PNV), and a former NonExecutive Chairman of Probiotec Ltd (ASX: PBP). Mr Johnston is a member of the Company's Remuneration and Audit & Risk Committees
Dr Leearne Hinch Chief Executive Officer Nov 2016
-
Mr Tony Di Pietro Joint Company SecretaryChief Financial Officer Jul 2020
-
Leearne Hinch Chief Executive Officer
-
Dr Gregory Rice Chief Scientific Officer
-
Tony Di Pietro Joint Company SecretaryChief Financial Officer
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
The Trust Company Australia Limited <Mof A/C> 6,086,400 6.62%
Moggs Creek Pty Ltd <Moggs Creek Super A/C> 4,886,671 5.32%
HSBC Custody Nominees (Australia) Limited 4,507,239 4.90%
Dr Irmgard Irminger-Finger 4,070,000 4.43%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 1,740,697 1.89%
J P Morgan Nominees Australia Pty Limited 1,239,572 1.35%
Traoj Pty Ltd <Traoj A/C> 1,102,933 1.20%
Mr Nathan Ryan Wagner 1,010,433 1.10%
Tony Walker 1,008,918 1.10%
Supergun Pty Ltd <Bricklanding Super Fund A/C> 1,000,000 1.09%
David Neate 902,257 0.98%
Washington H Soul Pattinson And Company Limited 745,162 0.81%
Dr Russell Kay Hancock 700,000 0.76%
Worldwise Enterprises Pty Ltd 684,354 0.74%
Citicorp Nominees Pty Limited 654,125 0.71%
UBS Nominees Pty Ltd 645,162 0.70%
Faraday Nominees Pty Limited <Bronte Investment A/C> 600,000 0.65%
B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> 584,516 0.64%
Ll&P Pty Ltd <The Andrew Solomons S/F A/C> 574,095 0.62%
B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> I 550,788 0.60%

Profile

since

Note